2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Gene Therapy, Immunotherapy, Monoclonal Antibody Therapy, Artificial Intelligence (AI), Deep Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly, Animal Model
PAPER

2163 The RNA helicase DHX9 couples RNA metabolism to genome maintenance and defines an actionable therapeutic vulnerability in multiple myeloma

Harshini Sriram, PhD, Srikanth Talluri, PhD2, Niti Amish Jhaveri3, Chenbing Sun, MD, PhD4, Anil Aktas-Samur, PhD5, Kushani Shah, PhD6, Mehmet Kemal Samur, PhD7, Masood Shammas, PhD8, Nikhil Munshi, MD9
1 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
3 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
4 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
5 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
8 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
9 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Background: Long noncoding RNAs (lncRNAs) have emerged as critical regulators of gene expression and cellular function, with growing evidence of their essential roles in cancer initiation, progression, and therapeutic resistance. The function of lncRNAs depends not only on their primary sequence but also on their higher-order RNA structures and dynamic interactions with RNA-binding proteins; mechanisms that remain poorly understood. We identified DHX9, an RNA helicase that regulates RNA structure, processing, and function as a strong dependency in multiple myeloma (MM) and investigated its functional role.
 
Methods: DHX9 expression was evaluated by Western blotting in 13 MM cell lines, CD138⁺ and CD138⁻ fractions from 4 MM patient samples, and peripheral blood mononuclear cells (PBMCs) from 7 healthy donors. The association of DHX9 expression with overall survival (OS) and event-free survival (EFS) was assessed using two independent MM patient datasets (MMRF and IFM70; n = 170). DHX9 was inhibited in MM cell lines or non-cancerous cell types [normal fibroblasts, HS5 bone marrow stromal cells and/or peripheral blood mononuclear cell (PBMC) samples] by shRNA-mediated knockdown or pharmacologic inhibitors (ATX968, DHX9-IN-5, and DHX9-IN-9), and cell viability was measured using the CellTiter-Glo Luminescent Cell Viability Assay. DNA:RNA hybrid levels were quantified by S9.6 dot blot analysis with or without RNase H treatment, while DNA damage was assessed by phospho-γH2AX expression using Western blotting. Homologous recombination (HR) activity was evaluated using homologous strand exchange and plasmid-based HR reporter assays, and RAD51 foci formation was analyzed by immunofluorescence staining followed by confocal microscopy.
 
Results: DHX9 was uniformly overexpressed in all MM cell lines and primary MM cells compared with normal PBMCs, as determined by Western blot analysis. High DHX9 expression was associated with inferior overall and event-free survival in both MM patient datasets. Consistent with these clinical observations, DepMap analyses also identified DHX9 as a strong genetic dependency across all 16 MM cell lines examined. Accordingly, shRNA-mediated DHX9 knockdown in H929 and RPMI8226 cells profoundly inhibited cell growth, resulting in near-complete loss of viability by day 7. Notably, as early as 48 hours after DHX9 depletion, impaired resolution of DNA:RNA hybrids, indicative of reduced helicase activity, was accompanied by a significant increase in sub-G1 cells (apoptosis) and a reduction in S-phase cells, supporting an essential role for DHX9 in DNA replication. In contrast, non-malignant cells, including normal fibroblasts, HS5 bone marrow stromal cells, and primary PBMCs, exhibited minimal sensitivity to DHX9 depletion, indicating a selective dependency on DHX9 in MM. DHX9 knockdown increased DNA:RNA hybrid levels by 2.3-fold in H929 cells and 1.5-fold in RPMI-8226 cells. This increase was abolished by RNase H treatment, confirming its specificity and demonstrating that DHX9 loss promotes R-loop accumulation. Consistent with defective R-loop resolution, DHX9 depletion increased γH2AX expression, reduced RAD51 recruitment to DNA damage foci, significantly impaired homologous recombination (HR) activity (P < 0.05), and markedly increased DNA breaks, establishing an essential role for DHX9 helicase activity in genome maintenance and HR-mediated DNA repair. Based on these findings, we evaluated the therapeutic potential of the DHX9 inhibitors ATX968, DHX9-IN-5, and DHX9-IN-9. Treatment for 5 days induced potent anti-myeloma activity across 5 MM cell lines, with mean IC₅₀ values of 0.55, 0.38, and 0.80 μM, respectively, compared with 45.2, 47.8, and 30.1 μM in normal PBMCs, corresponding to therapeutic indices of 82, 126, and 38.
 
Conclusion: Here, we identify DHX9 as a critical RNA helicase dependency in multiple myeloma that coordinates RNA metabolism and genome maintenance by resolving R-loops, promoting RAD51 recruitment to sites of DNA damage, and facilitating homologous recombination. These findings establish DHX9 as a promising therapeutic target whose inhibition selectively disrupts replication stress responses and genome maintenance to induce potent anti-myeloma activity.
Harshini Sriram, PhD: No relevant conflicts of interest to declare.